Gilead Sciences focuses on HIV/AIDS, liver disease, and serious cardiovascular and respiratory conditions. They develop and market therapies for infectious diseases, including hepatitis B and C. The company has broadened its focus to include pulmonary and cardiovascular diseases and cancer through acquisitions. Gilead's mission is to create possible by pursuing the impossible, and they have built a culture of excellence fueled by a passion for improving lives. They have around 12,000 employees who work together to prove the impossible wrong and start every day asking, "What's next?"